infantile malignant osteopetrosis[]

Rocket Pharmaceuticals receives FDA fast track designation for RP-L401 gene therapy for infantile malignant osteopetrosis
Pharmaceutical Business Review
Fri, 08/28/20 - 10:39 am
Rocket Pharmaceuticals
FDA
fast track
RP-L401
gene therapy
infantile malignant osteopetrosis[]